---
title: "Esperion Therapeutics, Inc. (ESPR.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/ESPR.US.md"
symbol: "ESPR.US"
name: "Esperion Therapeutics, Inc."
industry: "Pharmaceuticals"
datetime: "2026-04-17T06:28:40.477Z"
locales:
  - [en](https://longbridge.com/en/quote/ESPR.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/ESPR.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/ESPR.US.md)
---

# Esperion Therapeutics, Inc. (ESPR.US)

## Company Overview

Esperion Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C) in the United States. The company’s marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia cardiovascular disease who require additional lowering of LDL-C. Its products also include NILEMDO, an ATP Citrate Lyase (ACL) inhibitor that lowers LDL-C and cardiovascular risk by reducing cholesterol biosynthesis and up-regulating the LDL receptors; and NUSTENDI, a bempedoic acid and ezetimibe tablet to treat elevated LDL-C. It has license and collaboration agreements with Daiichi Sankyo Co.

| Item | Detail |
|------|--------|
| Industry | Pharmaceuticals |
| Exchange | US Market |
| Website | [www.esperion.com](https://www.esperion.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: C
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-04-17T04:30:10.000Z

**Overall: C (0.42)**

**Industry**: Pharmaceuticals

| Metric | Value |
|--------|-------|
| Industry Ranking | 75 / 188 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Blend - Stocks in which the company has both growth and mature businesses.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

**Multi Score**: C

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 21.31% |  |
| Net Profit YoY | 56.17% |  |
| P/B Ratio | -1.62 |  |
| Dividend Ratio | 0.00% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 490080045.85 |  |
| Revenue | 403135000.00 |  |

#### Multi Score Score: C

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | 6.57% | C |
| Profit Margin | -5.63% | D |
| Gross Margin | 56.08% | B |
| Revenue YoY | 21.31% | B |
| Net Profit YoY | 56.17% | B |
| Total Assets YoY | 35.50% | A |
| Net Assets YoY | 22.32% | A |
| Cash Flow Margin | 57.72% | C |
| OCF YoY | 21.31% | B |
| Turnover | 1.00 | A |
| Gearing Ratio | 164.82% | E |

```chart-data:radar
{
  "title": "Longbridge Financial Score - Esperion Therapeutics, Inc.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "21.31%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "56.17%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "-1.62",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "0.00%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "490080045.85",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "403135000.00",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "C",
      "indicators": [
        {
          "name": "ROE",
          "value": "6.57%",
          "rating": "C"
        },
        {
          "name": "Profit Margin",
          "value": "-5.63%",
          "rating": "D"
        },
        {
          "name": "Gross Margin",
          "value": "56.08%",
          "rating": "B"
        },
        {
          "name": "Revenue YoY",
          "value": "21.31%",
          "rating": "B"
        },
        {
          "name": "Net Profit YoY",
          "value": "56.17%",
          "rating": "B"
        },
        {
          "name": "Total Assets YoY",
          "value": "35.50%",
          "rating": "A"
        },
        {
          "name": "Net Assets YoY",
          "value": "22.32%",
          "rating": "A"
        },
        {
          "name": "Cash Flow Margin",
          "value": "57.72%",
          "rating": "C"
        },
        {
          "name": "OCF YoY",
          "value": "21.31%",
          "rating": "B"
        },
        {
          "name": "Turnover",
          "value": "1.00",
          "rating": "A"
        },
        {
          "name": "Gearing Ratio",
          "value": "164.82%",
          "rating": "E"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -21.61 | 207/188 | - | - | - |
| PB | -1.62 | 213/188 | - | - | - |
| PS (TTM) | 1.22 | 39/188 | 2.64 | 1.89 | 0.89 |
| Dividend Yield | 0.00% | - | - | - | - |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Eli Lilly (LLY.US) | A | A | B | E | B | B |
| 02 | ROCHE HOLDINGS AG (RHHVF.US) | A | B | B | D | B | B |
| 03 | Roche (RHHBY.US) | A | B | B | D | B | B |
| 04 | AstraZeneca (AZN.US) | A | B | C | D | B | B |
| 05 | NOVARTIS AG (NVS.US) | A | B | C | D | B | B |

## Institutional View

### Analyst Rating Distribution

> As of 2026-04-14T04:00:00.000Z

Total Analysts: **7**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 2 | 29% |
| Overweight | 3 | 43% |
| Hold | 1 | 14% |
| Underweight | 1 | 14% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 2.05 |
| Highest Target | 16.00 |
| Lowest Target | 1.78 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/ESPR.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/ESPR.US/norm.md)
- [Related News](https://longbridge.com/en/quote/ESPR.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/ESPR.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**